Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiotech Pharmaceuticals

This article was originally published in The Gray Sheet

Executive Summary

European launch of the Logic paclitaxel-coated coronary stent in early 2002 by Angiotech's partner Cook is anticipated to help Angiotech achieve profitability next year, company CEO William Hunter, MD, tells attendees of the Deutsche Banc Alex. Brown health care conference in Baltimore May 8-10. The launch would trigger royalty payments in the range of 5-10% to Angiotech for use of its paclitaxel delivery technology. Cook completed enrollment for its 180-patient ELUTES European study evaluating the drug-coated Logic on May 9. Toronto-based Angiotech also stands to benefit from a similar royalty payment from Boston Scientific, which is also developing a paclitaxel-coated stent under a separate agreement. Other device collaborations by the pharmaceutical firm include a $21 mil. agreement with C.R. Bard to develop paclitaxel-loaded surgical implants to treat restenosis in vein grafts, and with Alcon Labs for the treatment of proliferative ocular conditions. Clinical trials based on those agreements are slated for early 2002 and year-end, respectively
Advertisement

Related Content

Boston Scientific Disputes Cook Collaboration With Guidant On Coated Stents
Boston Scientific Disputes Cook Collaboration With Guidant On Coated Stents
Advertisement
UsernamePublicRestriction

Register

MT014846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel